9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(一水物)
| 中文名称 | 9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(一水物) |
|---|---|
| 中文同义词 | 9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤;9-(R)-2-(磷酰甲氧基)丙基腺嘌呤(R-PMPA);替诺福韦一水合物;9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(一水物);替诺福韦单水合物;9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(含水);(R)-(((1-(6-氨基-9H-嘌呤-9-基)丙烷-2-基)氧基)甲基)磷酸 水合物;替诺福韦一水化合物 |
| 英文名称 | 9-[(R)-2-(Phosphonomethoxy)propyl]adenine monohydrate |
| 英文同义词 | 9-[(R)-2-(Phosphonomethoxy)propyl]adenine monohydrate;Unii-99yxe507il;Tenofovir Monohydrate;Tenofovir (15 mg);Tenofovir (hydrate);[[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid monohydrate;PMPA Monohydrate;(R)-(((1-(6-Amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic acid hydrate |
| CAS号 | 206184-49-8 |
| 分子式 | C9H16N5O5P |
| 分子量 | 305.23 |
| EINECS号 | 808-956-8 |
| 相关类别 | 医药中间体;泰诺福韦中间体;对照品-杂质对照品;泰诺福韦系列;医药原料;ALIMTA;对照品 |
| Mol文件 | 206184-49-8.mol |
| 结构式 | ![]() |
9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(一水物) 性质
| 熔点 | 270-274oC |
|---|---|
| 储存条件 | 2-8°C |
| 溶解度 | 可溶于酸性水溶液(少许)、DMSO(少许) |
| 形态 | 固体 |
| 颜色 | 白色至类白色 |
| 稳定性 | 吸湿性 |
| 主要应用 | 药物(小分子) |
| InChI | 1S/C9H14N5O4P.H2O/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14;/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17);1H2/t6-;/m1./s1 |
| InChIKey | PINIEAOMWQJGBW-FYZOBXCZSA-N |
| SMILES | [P](=O)(O)(O)CO[C@@H](C[n]1c2ncnc(c2nc1)N)C.O |
Tenofovir shows cytotoxic effects on cell viability in HK-2 cells, with IC 50 values of 9.21 and 2.77 μM at 48 and 72 h in MTT assay, respectively. Tenofovir diminishes ATP levels in HK-2 cells. Tenofovir (3.0 to 28.8 μM) increases oxidative stress and protein carbonylation in HK-2 cells. Furthermore, Tenofovir induces apoptosis in HK-2 cells, and that apoptosis is induced via mitochondrial damage. Tenofovir and M48U1 formulated in 0.25% HEC each inhibits the replication of both R5-tropic HIV-1 BaL and X4-tropic HIV-1 IIIb in activated PBMCs, and inhibits several laboratory strains and patient-derived HIV-1 isolates. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibits synergistic antiretroviral activity against infection with R5-tropic HIV-1 BaL , and is not toxic to PBMCs.
Tenofovir Disoproxil Fumarate (20, 50, 140, or 300 mg/kg) administered to BLT mice, shows dose dependent activity during vaginal HIV challenge in BLT humanized mice. Tenofovir Disoproxil Fumarate (50, 140, 300 mg/kg) significantly reduces HIV transmission in BLT mice. Tenofovir Disoproxil Fumarate (0.5, 1.5, or 5.0 mg/kg/day, p.o.) induces a dose-dependent decline in serum viremia in woodchucks chronically infected with WHV. Tenofovir Disoproxil Fumarate administration is safe and effective in the woodchuck model of chronic HBV infection.
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 海关编码 | 2933599550 |
| 存储类别 | 6.1C - 可燃,急性毒性 类别3 毒性化合物或者引起慢性影响的化合物 |
| 危险性类别 | 急性毒性 类别3经口 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-13910AR | 9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(一水物) Tenofovir hydrate (Standard) | 206184-49-8 | 5 mg | 1000元 |
| 2026/06/05 | HY-13910AR | 9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(一水物) Tenofovir hydrate (Standard) | 206184-49-8 | 10 mg | 1400元 |
![9-[(R)-2-(磷酰甲氧基)丙基]腺嘌呤(一水物) 结构式](CAS/GIF/206184-49-8.gif)